The Experts below are selected from a list of 2391 Experts worldwide ranked by ideXlab platform

Lawrence J. Solin - One of the best experts on this subject based on the ideXlab platform.

  • outcome after treatment of patients with mammographically occult magnetic resonance imaging detected breast cancer presenting with Axillary Lymphadenopathy
    Clinical Breast Cancer, 2004
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Brian J. Czerniecki, Lawrence J. Solin
    Abstract:

    Abstract Although magnetic resonance imaging (MRI) for patients with mammographically occult breast cancer with Axillary Lymphadenopathy has been accepted for staging, treatment outcome data in this patient group is lacking. In this study, 16 patients, median age of 45 years (range, 27–66 years), presented with malignant Axillary Lymphadenopathy, negative mammograms, negative breast physical examination, and abnormal breast MRI. All 16 patients were found to have ≥ 1 suspicious lesions on breast MRI. Ten patients had a solitary enhancing lesion; 1 patient had 2 enhancing lesions; 3 patients had 3 enhancing lesions; 1 patient had a mass lesion and diffuse patchy enhancement in the breast; and 1 patient had regional enhancement but no discrete lesion on MRI. Six patients underwent breast-conservation surgery using MRI-guided wire localization and 10 patients had modified radical mastectomy. Fourteen patients received adjuvant chemotherapy and the remaining 2 patients received neoadjuvant chemotherapy. With a median follow-up of 5 years (range, 1.2–7.6 years), the 5-year actuarial local control was 100%, relapse-free survival was 74%, and overall survival was 87%. Three patients developed distant metastases. Two patients died from distant metastases, and 1 patient is alive with metastatic disease. One patient had a relapse in the contralateral axilla and was treated with paclitaxel and is disease free. Although the patient population is small, the outcome after treatment for this group of patients with a mammographically occult, MRI-detected breast cancer presenting with Axillary adenopathy is similar to the expected outcome for patients with breast cancer with positive Axillary lymph nodes.

  • Outcome After Treatment of Patients with Mammographically Occult, Magnetic Resonance Imaging—Detected Breast Cancer Presenting with Axillary Lymphadenopathy
    Clinical breast cancer, 2004
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Brian J. Czerniecki, Lawrence J. Solin
    Abstract:

    Abstract Although magnetic resonance imaging (MRI) for patients with mammographically occult breast cancer with Axillary Lymphadenopathy has been accepted for staging, treatment outcome data in this patient group is lacking. In this study, 16 patients, median age of 45 years (range, 27–66 years), presented with malignant Axillary Lymphadenopathy, negative mammograms, negative breast physical examination, and abnormal breast MRI. All 16 patients were found to have ≥ 1 suspicious lesions on breast MRI. Ten patients had a solitary enhancing lesion; 1 patient had 2 enhancing lesions; 3 patients had 3 enhancing lesions; 1 patient had a mass lesion and diffuse patchy enhancement in the breast; and 1 patient had regional enhancement but no discrete lesion on MRI. Six patients underwent breast-conservation surgery using MRI-guided wire localization and 10 patients had modified radical mastectomy. Fourteen patients received adjuvant chemotherapy and the remaining 2 patients received neoadjuvant chemotherapy. With a median follow-up of 5 years (range, 1.2–7.6 years), the 5-year actuarial local control was 100%, relapse-free survival was 74%, and overall survival was 87%. Three patients developed distant metastases. Two patients died from distant metastases, and 1 patient is alive with metastatic disease. One patient had a relapse in the contralateral axilla and was treated with paclitaxel and is disease free. Although the patient population is small, the outcome after treatment for this group of patients with a mammographically occult, MRI-detected breast cancer presenting with Axillary adenopathy is similar to the expected outcome for patients with breast cancer with positive Axillary lymph nodes.

  • Breast conservation treatment for patients presenting with Axillary Lymphadenopathy from presumed primary breast cancer: the role of breast magnetic resonance imaging for staging.
    Clinical breast cancer, 2002
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Lawrence J. Solin
    Abstract:

    Three female patients presented with malignant Axillary Lymphadenopathy presumed to be from primary breast cancer. No evidence of primary cancer was found in the breast on either mammography or breast magnetic resonance imaging (MRI). All 3 patients underwent Axillary lymph node dissection and systemic chemotherapy followed by radiation therapy to the breast and regional lymph nodes. Two patients remain relapse free with a follow-up of 3.7 years each. The third patient achieved locoregional control in the ipsilateral breast and regional lymph nodes but relapsed in the contralateral axilla. These 3 cases illustrate the potential for breast conservation treatment for patients presenting with Axillary adenopathy from a presumed primary breast cancer but without either mammographic or breast MRI findings.

Changhu Chen - One of the best experts on this subject based on the ideXlab platform.

  • outcome after treatment of patients with mammographically occult magnetic resonance imaging detected breast cancer presenting with Axillary Lymphadenopathy
    Clinical Breast Cancer, 2004
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Brian J. Czerniecki, Lawrence J. Solin
    Abstract:

    Abstract Although magnetic resonance imaging (MRI) for patients with mammographically occult breast cancer with Axillary Lymphadenopathy has been accepted for staging, treatment outcome data in this patient group is lacking. In this study, 16 patients, median age of 45 years (range, 27–66 years), presented with malignant Axillary Lymphadenopathy, negative mammograms, negative breast physical examination, and abnormal breast MRI. All 16 patients were found to have ≥ 1 suspicious lesions on breast MRI. Ten patients had a solitary enhancing lesion; 1 patient had 2 enhancing lesions; 3 patients had 3 enhancing lesions; 1 patient had a mass lesion and diffuse patchy enhancement in the breast; and 1 patient had regional enhancement but no discrete lesion on MRI. Six patients underwent breast-conservation surgery using MRI-guided wire localization and 10 patients had modified radical mastectomy. Fourteen patients received adjuvant chemotherapy and the remaining 2 patients received neoadjuvant chemotherapy. With a median follow-up of 5 years (range, 1.2–7.6 years), the 5-year actuarial local control was 100%, relapse-free survival was 74%, and overall survival was 87%. Three patients developed distant metastases. Two patients died from distant metastases, and 1 patient is alive with metastatic disease. One patient had a relapse in the contralateral axilla and was treated with paclitaxel and is disease free. Although the patient population is small, the outcome after treatment for this group of patients with a mammographically occult, MRI-detected breast cancer presenting with Axillary adenopathy is similar to the expected outcome for patients with breast cancer with positive Axillary lymph nodes.

  • Outcome After Treatment of Patients with Mammographically Occult, Magnetic Resonance Imaging—Detected Breast Cancer Presenting with Axillary Lymphadenopathy
    Clinical breast cancer, 2004
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Brian J. Czerniecki, Lawrence J. Solin
    Abstract:

    Abstract Although magnetic resonance imaging (MRI) for patients with mammographically occult breast cancer with Axillary Lymphadenopathy has been accepted for staging, treatment outcome data in this patient group is lacking. In this study, 16 patients, median age of 45 years (range, 27–66 years), presented with malignant Axillary Lymphadenopathy, negative mammograms, negative breast physical examination, and abnormal breast MRI. All 16 patients were found to have ≥ 1 suspicious lesions on breast MRI. Ten patients had a solitary enhancing lesion; 1 patient had 2 enhancing lesions; 3 patients had 3 enhancing lesions; 1 patient had a mass lesion and diffuse patchy enhancement in the breast; and 1 patient had regional enhancement but no discrete lesion on MRI. Six patients underwent breast-conservation surgery using MRI-guided wire localization and 10 patients had modified radical mastectomy. Fourteen patients received adjuvant chemotherapy and the remaining 2 patients received neoadjuvant chemotherapy. With a median follow-up of 5 years (range, 1.2–7.6 years), the 5-year actuarial local control was 100%, relapse-free survival was 74%, and overall survival was 87%. Three patients developed distant metastases. Two patients died from distant metastases, and 1 patient is alive with metastatic disease. One patient had a relapse in the contralateral axilla and was treated with paclitaxel and is disease free. Although the patient population is small, the outcome after treatment for this group of patients with a mammographically occult, MRI-detected breast cancer presenting with Axillary adenopathy is similar to the expected outcome for patients with breast cancer with positive Axillary lymph nodes.

  • Breast conservation treatment for patients presenting with Axillary Lymphadenopathy from presumed primary breast cancer: the role of breast magnetic resonance imaging for staging.
    Clinical breast cancer, 2002
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Lawrence J. Solin
    Abstract:

    Three female patients presented with malignant Axillary Lymphadenopathy presumed to be from primary breast cancer. No evidence of primary cancer was found in the breast on either mammography or breast magnetic resonance imaging (MRI). All 3 patients underwent Axillary lymph node dissection and systemic chemotherapy followed by radiation therapy to the breast and regional lymph nodes. Two patients remain relapse free with a follow-up of 3.7 years each. The third patient achieved locoregional control in the ipsilateral breast and regional lymph nodes but relapsed in the contralateral axilla. These 3 cases illustrate the potential for breast conservation treatment for patients presenting with Axillary adenopathy from a presumed primary breast cancer but without either mammographic or breast MRI findings.

Eleanor E.r. Harris - One of the best experts on this subject based on the ideXlab platform.

  • outcome after treatment of patients with mammographically occult magnetic resonance imaging detected breast cancer presenting with Axillary Lymphadenopathy
    Clinical Breast Cancer, 2004
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Brian J. Czerniecki, Lawrence J. Solin
    Abstract:

    Abstract Although magnetic resonance imaging (MRI) for patients with mammographically occult breast cancer with Axillary Lymphadenopathy has been accepted for staging, treatment outcome data in this patient group is lacking. In this study, 16 patients, median age of 45 years (range, 27–66 years), presented with malignant Axillary Lymphadenopathy, negative mammograms, negative breast physical examination, and abnormal breast MRI. All 16 patients were found to have ≥ 1 suspicious lesions on breast MRI. Ten patients had a solitary enhancing lesion; 1 patient had 2 enhancing lesions; 3 patients had 3 enhancing lesions; 1 patient had a mass lesion and diffuse patchy enhancement in the breast; and 1 patient had regional enhancement but no discrete lesion on MRI. Six patients underwent breast-conservation surgery using MRI-guided wire localization and 10 patients had modified radical mastectomy. Fourteen patients received adjuvant chemotherapy and the remaining 2 patients received neoadjuvant chemotherapy. With a median follow-up of 5 years (range, 1.2–7.6 years), the 5-year actuarial local control was 100%, relapse-free survival was 74%, and overall survival was 87%. Three patients developed distant metastases. Two patients died from distant metastases, and 1 patient is alive with metastatic disease. One patient had a relapse in the contralateral axilla and was treated with paclitaxel and is disease free. Although the patient population is small, the outcome after treatment for this group of patients with a mammographically occult, MRI-detected breast cancer presenting with Axillary adenopathy is similar to the expected outcome for patients with breast cancer with positive Axillary lymph nodes.

  • Outcome After Treatment of Patients with Mammographically Occult, Magnetic Resonance Imaging—Detected Breast Cancer Presenting with Axillary Lymphadenopathy
    Clinical breast cancer, 2004
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Brian J. Czerniecki, Lawrence J. Solin
    Abstract:

    Abstract Although magnetic resonance imaging (MRI) for patients with mammographically occult breast cancer with Axillary Lymphadenopathy has been accepted for staging, treatment outcome data in this patient group is lacking. In this study, 16 patients, median age of 45 years (range, 27–66 years), presented with malignant Axillary Lymphadenopathy, negative mammograms, negative breast physical examination, and abnormal breast MRI. All 16 patients were found to have ≥ 1 suspicious lesions on breast MRI. Ten patients had a solitary enhancing lesion; 1 patient had 2 enhancing lesions; 3 patients had 3 enhancing lesions; 1 patient had a mass lesion and diffuse patchy enhancement in the breast; and 1 patient had regional enhancement but no discrete lesion on MRI. Six patients underwent breast-conservation surgery using MRI-guided wire localization and 10 patients had modified radical mastectomy. Fourteen patients received adjuvant chemotherapy and the remaining 2 patients received neoadjuvant chemotherapy. With a median follow-up of 5 years (range, 1.2–7.6 years), the 5-year actuarial local control was 100%, relapse-free survival was 74%, and overall survival was 87%. Three patients developed distant metastases. Two patients died from distant metastases, and 1 patient is alive with metastatic disease. One patient had a relapse in the contralateral axilla and was treated with paclitaxel and is disease free. Although the patient population is small, the outcome after treatment for this group of patients with a mammographically occult, MRI-detected breast cancer presenting with Axillary adenopathy is similar to the expected outcome for patients with breast cancer with positive Axillary lymph nodes.

  • Breast conservation treatment for patients presenting with Axillary Lymphadenopathy from presumed primary breast cancer: the role of breast magnetic resonance imaging for staging.
    Clinical breast cancer, 2002
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Lawrence J. Solin
    Abstract:

    Three female patients presented with malignant Axillary Lymphadenopathy presumed to be from primary breast cancer. No evidence of primary cancer was found in the breast on either mammography or breast magnetic resonance imaging (MRI). All 3 patients underwent Axillary lymph node dissection and systemic chemotherapy followed by radiation therapy to the breast and regional lymph nodes. Two patients remain relapse free with a follow-up of 3.7 years each. The third patient achieved locoregional control in the ipsilateral breast and regional lymph nodes but relapsed in the contralateral axilla. These 3 cases illustrate the potential for breast conservation treatment for patients presenting with Axillary adenopathy from a presumed primary breast cancer but without either mammographic or breast MRI findings.

Susan G. Orel - One of the best experts on this subject based on the ideXlab platform.

  • outcome after treatment of patients with mammographically occult magnetic resonance imaging detected breast cancer presenting with Axillary Lymphadenopathy
    Clinical Breast Cancer, 2004
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Brian J. Czerniecki, Lawrence J. Solin
    Abstract:

    Abstract Although magnetic resonance imaging (MRI) for patients with mammographically occult breast cancer with Axillary Lymphadenopathy has been accepted for staging, treatment outcome data in this patient group is lacking. In this study, 16 patients, median age of 45 years (range, 27–66 years), presented with malignant Axillary Lymphadenopathy, negative mammograms, negative breast physical examination, and abnormal breast MRI. All 16 patients were found to have ≥ 1 suspicious lesions on breast MRI. Ten patients had a solitary enhancing lesion; 1 patient had 2 enhancing lesions; 3 patients had 3 enhancing lesions; 1 patient had a mass lesion and diffuse patchy enhancement in the breast; and 1 patient had regional enhancement but no discrete lesion on MRI. Six patients underwent breast-conservation surgery using MRI-guided wire localization and 10 patients had modified radical mastectomy. Fourteen patients received adjuvant chemotherapy and the remaining 2 patients received neoadjuvant chemotherapy. With a median follow-up of 5 years (range, 1.2–7.6 years), the 5-year actuarial local control was 100%, relapse-free survival was 74%, and overall survival was 87%. Three patients developed distant metastases. Two patients died from distant metastases, and 1 patient is alive with metastatic disease. One patient had a relapse in the contralateral axilla and was treated with paclitaxel and is disease free. Although the patient population is small, the outcome after treatment for this group of patients with a mammographically occult, MRI-detected breast cancer presenting with Axillary adenopathy is similar to the expected outcome for patients with breast cancer with positive Axillary lymph nodes.

  • Outcome After Treatment of Patients with Mammographically Occult, Magnetic Resonance Imaging—Detected Breast Cancer Presenting with Axillary Lymphadenopathy
    Clinical breast cancer, 2004
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Brian J. Czerniecki, Lawrence J. Solin
    Abstract:

    Abstract Although magnetic resonance imaging (MRI) for patients with mammographically occult breast cancer with Axillary Lymphadenopathy has been accepted for staging, treatment outcome data in this patient group is lacking. In this study, 16 patients, median age of 45 years (range, 27–66 years), presented with malignant Axillary Lymphadenopathy, negative mammograms, negative breast physical examination, and abnormal breast MRI. All 16 patients were found to have ≥ 1 suspicious lesions on breast MRI. Ten patients had a solitary enhancing lesion; 1 patient had 2 enhancing lesions; 3 patients had 3 enhancing lesions; 1 patient had a mass lesion and diffuse patchy enhancement in the breast; and 1 patient had regional enhancement but no discrete lesion on MRI. Six patients underwent breast-conservation surgery using MRI-guided wire localization and 10 patients had modified radical mastectomy. Fourteen patients received adjuvant chemotherapy and the remaining 2 patients received neoadjuvant chemotherapy. With a median follow-up of 5 years (range, 1.2–7.6 years), the 5-year actuarial local control was 100%, relapse-free survival was 74%, and overall survival was 87%. Three patients developed distant metastases. Two patients died from distant metastases, and 1 patient is alive with metastatic disease. One patient had a relapse in the contralateral axilla and was treated with paclitaxel and is disease free. Although the patient population is small, the outcome after treatment for this group of patients with a mammographically occult, MRI-detected breast cancer presenting with Axillary adenopathy is similar to the expected outcome for patients with breast cancer with positive Axillary lymph nodes.

  • Breast conservation treatment for patients presenting with Axillary Lymphadenopathy from presumed primary breast cancer: the role of breast magnetic resonance imaging for staging.
    Clinical breast cancer, 2002
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Lawrence J. Solin
    Abstract:

    Three female patients presented with malignant Axillary Lymphadenopathy presumed to be from primary breast cancer. No evidence of primary cancer was found in the breast on either mammography or breast magnetic resonance imaging (MRI). All 3 patients underwent Axillary lymph node dissection and systemic chemotherapy followed by radiation therapy to the breast and regional lymph nodes. Two patients remain relapse free with a follow-up of 3.7 years each. The third patient achieved locoregional control in the ipsilateral breast and regional lymph nodes but relapsed in the contralateral axilla. These 3 cases illustrate the potential for breast conservation treatment for patients presenting with Axillary adenopathy from a presumed primary breast cancer but without either mammographic or breast MRI findings.

Mitchell D. Schnall - One of the best experts on this subject based on the ideXlab platform.

  • outcome after treatment of patients with mammographically occult magnetic resonance imaging detected breast cancer presenting with Axillary Lymphadenopathy
    Clinical Breast Cancer, 2004
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Brian J. Czerniecki, Lawrence J. Solin
    Abstract:

    Abstract Although magnetic resonance imaging (MRI) for patients with mammographically occult breast cancer with Axillary Lymphadenopathy has been accepted for staging, treatment outcome data in this patient group is lacking. In this study, 16 patients, median age of 45 years (range, 27–66 years), presented with malignant Axillary Lymphadenopathy, negative mammograms, negative breast physical examination, and abnormal breast MRI. All 16 patients were found to have ≥ 1 suspicious lesions on breast MRI. Ten patients had a solitary enhancing lesion; 1 patient had 2 enhancing lesions; 3 patients had 3 enhancing lesions; 1 patient had a mass lesion and diffuse patchy enhancement in the breast; and 1 patient had regional enhancement but no discrete lesion on MRI. Six patients underwent breast-conservation surgery using MRI-guided wire localization and 10 patients had modified radical mastectomy. Fourteen patients received adjuvant chemotherapy and the remaining 2 patients received neoadjuvant chemotherapy. With a median follow-up of 5 years (range, 1.2–7.6 years), the 5-year actuarial local control was 100%, relapse-free survival was 74%, and overall survival was 87%. Three patients developed distant metastases. Two patients died from distant metastases, and 1 patient is alive with metastatic disease. One patient had a relapse in the contralateral axilla and was treated with paclitaxel and is disease free. Although the patient population is small, the outcome after treatment for this group of patients with a mammographically occult, MRI-detected breast cancer presenting with Axillary adenopathy is similar to the expected outcome for patients with breast cancer with positive Axillary lymph nodes.

  • Outcome After Treatment of Patients with Mammographically Occult, Magnetic Resonance Imaging—Detected Breast Cancer Presenting with Axillary Lymphadenopathy
    Clinical breast cancer, 2004
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Brian J. Czerniecki, Lawrence J. Solin
    Abstract:

    Abstract Although magnetic resonance imaging (MRI) for patients with mammographically occult breast cancer with Axillary Lymphadenopathy has been accepted for staging, treatment outcome data in this patient group is lacking. In this study, 16 patients, median age of 45 years (range, 27–66 years), presented with malignant Axillary Lymphadenopathy, negative mammograms, negative breast physical examination, and abnormal breast MRI. All 16 patients were found to have ≥ 1 suspicious lesions on breast MRI. Ten patients had a solitary enhancing lesion; 1 patient had 2 enhancing lesions; 3 patients had 3 enhancing lesions; 1 patient had a mass lesion and diffuse patchy enhancement in the breast; and 1 patient had regional enhancement but no discrete lesion on MRI. Six patients underwent breast-conservation surgery using MRI-guided wire localization and 10 patients had modified radical mastectomy. Fourteen patients received adjuvant chemotherapy and the remaining 2 patients received neoadjuvant chemotherapy. With a median follow-up of 5 years (range, 1.2–7.6 years), the 5-year actuarial local control was 100%, relapse-free survival was 74%, and overall survival was 87%. Three patients developed distant metastases. Two patients died from distant metastases, and 1 patient is alive with metastatic disease. One patient had a relapse in the contralateral axilla and was treated with paclitaxel and is disease free. Although the patient population is small, the outcome after treatment for this group of patients with a mammographically occult, MRI-detected breast cancer presenting with Axillary adenopathy is similar to the expected outcome for patients with breast cancer with positive Axillary lymph nodes.

  • Breast conservation treatment for patients presenting with Axillary Lymphadenopathy from presumed primary breast cancer: the role of breast magnetic resonance imaging for staging.
    Clinical breast cancer, 2002
    Co-Authors: Changhu Chen, Susan G. Orel, Eleanor E.r. Harris, Mitchell D. Schnall, Lawrence J. Solin
    Abstract:

    Three female patients presented with malignant Axillary Lymphadenopathy presumed to be from primary breast cancer. No evidence of primary cancer was found in the breast on either mammography or breast magnetic resonance imaging (MRI). All 3 patients underwent Axillary lymph node dissection and systemic chemotherapy followed by radiation therapy to the breast and regional lymph nodes. Two patients remain relapse free with a follow-up of 3.7 years each. The third patient achieved locoregional control in the ipsilateral breast and regional lymph nodes but relapsed in the contralateral axilla. These 3 cases illustrate the potential for breast conservation treatment for patients presenting with Axillary adenopathy from a presumed primary breast cancer but without either mammographic or breast MRI findings.